| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nov 3, 2022 | UTHR United Therapeutics Corp | Causey Christopher59 | Director | Sell | 7,500 | $250.00 | $1,875,024.25 | -46.9% | -2.0% | -15.4% | |
| Nov 3, 2022 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 8,408 | $125.00 | $1,050,996.96 | -21.8% | -11.2% | -9.4% | |
| Nov 3, 2022 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 9,368 | $125.02 | $1,171,182.95 | -23.0% | -11.2% | -9.4% | |
| Nov 2, 2022 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 6,131 | $362.07 | $2,219,851.17 | - | -2.8% | +63.9% | |
| Nov 2, 2022 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 10,400 | $120.28 | $1,250,899.00 | -15.1% | -9.1% | -7.1% | |
| Nov 2, 2022 | UTHR United Therapeutics Corp | Rothblatt Martine A58 | Chairperson &CEO | Sell | 16,000 | $239.93 | $3,838,893.46 | -14.8% | +3.8% | -10.0% | |
| Nov 2, 2022 | MRK Merck & Co., Inc. | Frazier Kenneth C | Executive Chair | Sell | 600,000 | $99.86 | $59,914,706.34 | -13.9% | +8.8% | +6.3% | |
| Nov 1, 2022 | UTHR United Therapeutics Corp | Sullivan Louis W62 | Director | Sell | 700 | $230.28 | $161,196.00 | -5.4% | +13.3% | -1.9% | |
| Nov 1, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $31.13 | $15,565.30 | -0.6% | -3.1% | +45.3% | |
| Oct 31, 2022 | VRNO Verano Holdings Corp. | Thompson Destiny Lynn | Chief People Officer | Sell | 2,907 | $5.23 | $15,200.12 | -26.7% | - | - | |
| Oct 31, 2022 | NBIX Neurocrine Biosciences Inc | Lyons Gary A54 | Director | Sell | 15,000 | $114.76 | $1,721,403.00 | -6.9% | -5.9% | -3.6% | |
| Oct 31, 2022 | NBIX Neurocrine Biosciences Inc | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 1,295 | $114.12 | $147,785.40 | -30.7% | -5.9% | -3.6% | |
| Oct 31, 2022 | MRK Merck & Co., Inc. | Frazier Kenneth C | Executive Chair | Sell | 867,084 | $100.44 | $87,090,363.48 | -16.4% | +5.5% | +4.3% | |
| Oct 31, 2022 | CPIX Cumberland Pharmaceuticals Inc | Young Caroline52 | Director | Buy | 500 | $2.49 | $1,247.40 | +0.1% | +9.8% | -19.5% | |
| Oct 31, 2022 | CPIX Cumberland Pharmaceuticals Inc | Galante Joseph C47 | Director | Buy | 1,625 | $2.49 | $4,054.05 | +0.1% | +9.8% | -19.5% | |
| Oct 31, 2022 | CPIX Cumberland Pharmaceuticals Inc | Krogulski Kenneth54 | Director | Buy | 2,625 | $2.49 | $6,548.85 | - | +9.8% | -19.5% | |
| Oct 31, 2022 | CPIX Cumberland Pharmaceuticals Inc | Jones James53 | Director | Buy | 775 | $2.49 | $1,933.47 | +0.1% | +9.8% | -19.5% | |
| Oct 28, 2022 | MRK Merck & Co., Inc. | Zachary Jennifer | EVP, General Counsel | Sell | 165,255 | $99.38 | $16,422,892.71 | -53.9% | +6.8% | +4.8% | |
| Oct 28, 2022 | MRK Merck & Co., Inc. | Mizell Steven52 | EVP, Chief Hr Officer | Sell | 25,000 | $99.63 | $2,490,720.00 | -25.7% | +6.8% | +4.8% | |
| Oct 28, 2022 | MRK Merck & Co., Inc. | Oosthuizen Johannes Jacobus | President, U.s. Market | Sell | 3,633 | $100.21 | $364,064.75 | -25.0% | +6.8% | +4.8% | |
| Oct 28, 2022 | MRK Merck & Co., Inc. | Karachun Rita A | Sr. VP Fince-global Controller | Sell | 31,997 | $100.34 | $3,210,684.57 | -43.8% | +6.8% | +4.8% | |
| Oct 28, 2022 | MRK Merck & Co., Inc. | Chattopadhyay Sanat | Exe V-p &Pres. Mmd | Sell | 100,292 | $100.10 | $10,039,379.64 | -68.7% | +6.8% | +4.8% | |
| Oct 28, 2022 | MRK Merck & Co., Inc. | Deluca Richard R.45 | EVP&Pres, Merck Animal Heallth | Sell | 164,557 | $100.26 | $16,499,093.68 | -54.6% | +6.8% | +4.8% | |
| Oct 28, 2022 | TXMD Therapeuticsmd, Inc. | Rubric Capital Management LP | 10% Owner | Buy | 7,000 | $1,000.00 | $7,000,000.00 | +31.8% | -14.8% | -66.3% | |
| Oct 27, 2022 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 10,000 | $115.03 | $1,150,297.26 | -14.6% | -4.4% | -6.8% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.